• The KEYNOTE-B79 and IMMUNICY-1 clinical trials, which respectively evaluate CYAD-101 and CYAD-211, the company’s candidate allogeneic CAR-T cells, are expected to generate key data throughout 2022
• The company’s proprietary, non-genetic shRNA technology received clinical validation as a new platform for the development of next-generation allogeneic CAR-T cells
• The preclinical allogeneic shRNA-based pipeline continues to advance with the candidate armored CAR-T cell CYAD-203, which expresses IL-18, as well as with discovery programs focused on patented T-cell protein-targeting binders. TAG72 and GPC3
• A private placement of $ 32.5 million was recently received from a subsidiary of the Fortress Investment Group to fund research and development of the company’s current allogeneic CAR-T pipeline.
• On December 31, 2021, the company ended its financial year with an unaudited cash position of 30 million EUR (34 million USD)